Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744739 | 0.81 | HDAC3 (0.52) | HTTLMNAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19870991 | 0.80 | KCNN4 (0.57) | HTTLMNAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2845025 | 0.80 | HDAC3 (0.61) | HTTLMNAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10694349 | 0.79 | HTT (0.53) | HTTLMNAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10568366 | 0.78 | HTT (0.51) | HTTLMNAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13270940 | 0.78 | MAPT (0.57) | HTTLMNAL3MBTL1ALDH1A1CNR1 | |
| SCHEMBL4373828 | 0.78 | HDAC3 (0.70) | HTTLMNAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21688073 | 0.78 | HDAC3 (0.48) | HTTLMNAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL24671951 | 0.78 | HTT (0.60) | HTTLMNAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10692938 | 0.78 | LMNA (0.51) | HTTLMNAL3MBTL1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888525-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-02-20 | — | — | EP | claimed |
| WO-2006117754-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| EP-1620087-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2006-02-01 | — | — | EP | claimed |
| WO-2004089364-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-10-21 | — | — | WO | claimed |
| CN-115551864-A | Substituted tricyclic amides, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-12-30 | — | — | CN | disclosed |
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | disclosed |
| CN-101679596-B | Super-high refractive index optical resin composition having high heat deflection temperature and excellent thermal stability, optical lens using same and method for manufacturing the optical lens | KOC SOLUTION CO LTD | 2013-02-20 | — | — | CN | disclosed |
| CN-101679596-A | Super-high refractive index optical resin composition having high heat deflection temperature and excellent thermal stability, optical lens using same and method for manufacturing the optical lens | SHIN DAE SPECIALTIES CO LTD | 2010-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10207993-B2 | Compounds as anti-tubercular agents | FNTB, G6PD, PGGT1B | HTT 4686/4885LMNA 3630/4885L3MBTL1 4594/4885 |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | HTT 4711/4885LMNA 3576/4885L3MBTL1 4494/4885 |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | HTT 4711/4885LMNA 3576/4885L3MBTL1 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.